Sentences with phrase «for dyslipidemia»

Not exact matches

Prior to this role, Ryan was an Associate on the Cardio - Renal Team within the TechAtlas division of RA Capital, where he mapped competitive landscapes of drugs and medical devices for disease indications and capabilities, with a focus on coronary artery disease, stroke, and dyslipidemia.

The extent to which NAFLD itself, rather than associated conditions such as diabetes, obesity, or atherogenic dyslipidemia, is responsible for increased cardiovascular death has been a matter of debate.

Whilst several personal risk factors for developing heart disease have been identified, including smoking, diabetes and dyslipidemia, the contribution of environmental contaminants has received comparatively less attention.

C57BL / 6 mice were fed the diet for 23 weeks and developed obesity, insulin resistance, dyslipidemia as well as liver steatosis, inflammation and fibrosis.

Hypertension (high blood pressure) and dyslipidemia (abnormal lipid levels) are risk factors for heart disease and stroke.

Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters

The second study again took healthy rats and fed that sucrose - rich diet for 3 months so that they would develop insulin resistance and dyslipidemia.

Since chia seeds have such high amounts of alpha - linoleic acid and dietary fiber, scientists have tried to find out how they can help with the prevention of metabolic conditions like dyslipidemia, which is the presence of extra fat in the blood and insulin resistance, the two key reasons for developing diabetes.

This means that tomatoes make it possible for individuals to easily manage the start of dyslipidemia by way of their daily diet.

For example, high - fructose diets were shown to cause dyslipidemia in healthy people with and without a family history of type II diabetes, a recent study showed15.

Because of its mind - body emphasis and its ability to address not only physical risk factors for DM2 such as hypertension and dyslipidemia, but also psychological factors like perceived stress, depression and emotional wellbeing, yoga may be an important addition to DM2 prevention and management.

Research supports the use of coconut oil for obesity, dyslipidemia, insulin resistance, hypertension, and pathologically elevated LDL, all of which constitute risk factors for diabetes, cardiovascular disease, and Alzheimer's, the last of which is being re-conceptualized as type 3 diabetes (Fernando et al., 2015).

Women with PCOS tend to have higher levels of insulin and, as a result, are at an increased risk for metabolic conditions such as dyslipidemia (high triglycerides and low HDL levels), type 2 diabetes, and metabolic syndrome.

These fat cells actually produce inflammatory chemicals, decreasing insulin sensitivity and increasing likelihood for developing metabolic disorders (diabetes, dyslipidemia and more).

BPA causes hyperinsulinemia or insulin resistance, a forerunner for Type ‑ 2 diabetes, hypertension, and dyslipidemia.

Testing should be considered for all individuals who are overweight or obese (BMI 25 or greater) plus the additional risks: first degree relative with diabetes mellitus or Polycystic Ovarian Disease, history of gestational diabetes, thyroid disorder, HDL level < 35 mg / dl and / or Triglyceride level > 250 mg / dl, hypertensive, sedentary, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) on previous testing, women who delivered macrosomic baby (e.g. weighing > 9 lbs), and other clinical conditions such as acanthosis nigricans, severe obesity, polycystic ovary syndrome, dyslipidemia.

Did you know that cucumber, or Cucumis sativus, is considered a medicinal food for the treatment of dyslipidemia (high cholesterol)?

Hypertension (high blood pressure) and dyslipidemia (abnormal lipid levels) are risk factors for heart disease and stroke.

We all know about the variety of risk factors that have been associated with PCOS, including obesity, glucose intolerance, and dyslipidemia, which leads to a significantly increased risk for type 2 diabetes mellitus and cardiovascular disease.

For a large proportion of the population, however, the effect of higher - carbohydrate diets, particularly those enriched in refined carbohydrates, coupled with the rising incidence of overweight and obesity, creates a metabolic state that can favor a worsening of the atherogenic dyslipidemia that is characterized by elevated triglycerides, reduced HDL cholesterol, and increased concentrations of small, dense LDL particles (6, 7).

Perform nutritional assessments for clients with diabetes, prediabetes, heart disease, dyslipidemia, thyroid disease, metabolic syndrome, obesity, celiac disease and other diagnoses.

Quintiles / Abbott Laboratories, Brooklyn • NY 2009 — 2011 Hospital / Dyslipidemia Representative Exceeded sales expectations for Niaspan ®, Simcor ® and Trilipix ® by building strong relationships with physicians and closing calls by using professionally assertive sales techniques.

Inclusion criteria were (1) BMI > 97th percentile for age and gender or BMI > 90th percentile20 with the presence of additional risk factors or diseases (eg, hypertension, dyslipidemia, diabetes, orthopedic problems), (2) referral for weight - reduction treatment by a local pediatrician, and (3) attendance at a regular school.